Chardan lowered the firm’s price target on Metagenomi (MGX) to $11 from $12. The firm updated its model for Q2 financials and takes a slightly ...

Metagenomi, Inc. ( ($MGX) ) has released its Q2 earnings. Here is a breakdown of the information Metagenomi, Inc. presented to its investors.

Metagenomi Inc. Quarterly cash flow by MarketWatch. View MGX net cash flow, operating cash flow, operating expenses and cash dividends.

In May 2025, the Company reported additional long-term data from its nonhuman primate (“NHP”) study that demonstrated durable and consistent FVIII activity levels through approximately 19 months. Mean ...

Metagenomi, Inc. announced positive results from a nonhuman primate study on their hemophilia A therapy, showing sustained factor VIII (FVIII) activity for around 19 months with a favorable safety ...

Metagenomi Inc. (MGX) on Tuesday reported a loss of $19.9 million in its second quarter.

Metagenomi, Inc., a precision genetic medicines company, announced the successful integration of a large, therapeutically relevant gene into human cells using its innovative CAST system, which was ...

Metagenomi completed its initial public offering on February 13, 2024, selling 6.25 million shares at $15 per share. However, less than three months later, on May 1, 2024, Metagenomi announced ...

Metagenomi raised $175 million in January 2022. According to the IPO paperwork, the biotech had $292.9 million in cash and equivalents as of September 2023, at which point collaboration revenue ...

expand Brian Thomas, CEO of Metagenomi Inc. Todd Johnson | San Francisco Business Times By Kevin Truong – Assistant Managing Editor, San Francisco Business Times May 6, 2021 ...

Metagenomi says the oversubscribed $175 million Series B financing it completed Tuesday will enable it to advance its lead in vivo and ex vivo gene editing therapy programs into the clinic.

Metagenomi’s goal is to adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific, and have a decreased risk ...